Partnering

Out-licensing: INT-777

Intercept is evaluating out-licensing opportunities for this preclinical product candidate.

INT-777 (6alpha-ethyl-23(S)-methyl-cholic acid, 6-EMCA) is an orally administered TGR5 agonist that is derived from the primary human bile acid cholic acid. Our in vitro studies have shown that INT-777 has the potential to selectively target TGR5, a G-protein coupled receptor that has been shown to directly regulate the release of glucagon-like peptide-1, or GLP-1, in the intestine with resulting insulin-sensitizing effects. We have completed the preclinical studies necessary for the filing of an IND. We own exclusive worldwide, royalty-free rights to INT-777.

  • Control glucose homeostasis
  • Inhibit atherosclerosis by reducing macrophage inflammation and lipid loading
  • Prevent diabetic kidney disease

Contact: All partnering inquiries should be directed to Corporate Development.

Current collaborationsa

Sumitomo Dainippon Pharma Co. Ltd.

Intercept entered into a license agreement with Sumitomo Dainippon Pharma Co. Ltd. Sumitomo Dainippon has an exclusive license to research, develop, and commercialize obeticholic acid (OCA) as a therapeutic for the treatment of primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) in China (excluding Taiwan). We granted Sumitomo Dainippon an option under the agreement to obtain an exclusive license to commercialize OCA for indications other than PBC and NASH on the same terms as are set forth in the agreement.

aNote: please review our documents filed with the SEC for a complete and comprehensive disclosure of our strategic collaborations and research arrangements.